Intestinal barrier dysfunction orchestrates the onset of inflammatory host-microbiome cross-talk in a human gut inflammation-on-a-chip

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 45, 2018, Pages E10539-E10547

  Shin, Woojung ^a   Kim, Hyun Jung ^a,b  

^a The University of Texas at Austin   (United States)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Barrier function; Disease model; Gut inflammation on a chip; Inflammation; Microbiome

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; DEXTRAN SULFATE; PROBIOTIC AGENT;

ARTICLE; CACO 2BBE CELL LINE; CELL ACTIVATION; CELL CONTACT; CELL INTERACTION; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; ENTERITIS; EPITHELIAL CELL LINE; EPITHELIUM CELL; ESCHERICHIA COLI; EXPERIMENTAL INFLAMMATION; GUT INFLAMMATION ON A CHIP; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INTESTINE EPITHELIAL BARRIER DYSFUNCTION; INTESTINE EPITHELIUM; INTESTINE FLORA; INTESTINE FUNCTION DISORDER; MEMBRANE PERMEABILITY; MOLECULAR INTERACTION; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROOF OF CONCEPT; DRUG EFFECT; HOMEOSTASIS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INFLAMMATION; INTESTINE MUCOSA; MICROBIOLOGY;

DEXTRAN SULFATE; GASTROINTESTINAL MICROBIOME; HOMEOSTASIS; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLAMMATION; INTESTINAL MUCOSA; OXIDATIVE STRESS; PROBIOTICS;

EID: 85056086517     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1810819115     Document Type: Article

References (44)

1. Kim HJ, Ingber DE (2013) Gut-on-a-chip microenvironment induces human intestinal cells to undergo villus differentiation. Integr Biol 5:1130-1140.
2. Park G-S, et al. (2017) Emulating host-microbiome ecosystem of human gastrointestinal tract in vitro. Stem Cell Rev 13:321-334.
3. Bein A, et al. (2018) Microfluidic organ-on-a-chip models of human intestine. Cell Mol Gastroenterol Hepatol 5:659-668.
4. Kim HJ, Li H, Collins JJ, Ingber DE (2016) Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. Proc Natl Acad Sci USA 113:E7-E15.
5. Solomon L, et al. (2010) The dextran sulphate sodium (DSS) model of colitis: An overview. Comp Clin Pathol 19:235-239.
6. Chassaing B, Aitken JD, Malleshappa M, Vijay‐Kumar M (2014) Dextran sulfate sodium (DSS)‐induced colitis in mice. Curr Protoc Immunol 104:15.25.1-15.25.14.
7. Kim HJ, Lee J, Choi JH, Bahinski A, Ingber DE (2016) Co-culture of living microbiome with microengineered human intestinal villi in a gut-on-a-chip microfluidic device. J Vis Exp e54344.
8. Kuo JC, et al. (2016) Detection of colorectal dysplasia using fluorescently labelled lectins. Sci Rep 6:24231.
9. Piechota-Polanczyk A, Fichna J (2014) Review article: The role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases. Naunyn Schmiedebergs Arch Pharmacol 387:605-620.
10. O'Connor J-E, et al. (2017) Cytomics of oxidative stress: Probes and problems. Single Cell Analysis (Springer, Singapore), pp 83-118.
11. Guo S, et al. (2015) Lipopolysaccharide regulation of intestinal tight junction permeability is mediated by TLR4 signal transduction pathway activation of FAK and MyD88. J Immunol 195:4999-5010.
12. Farina C, Arosio M, Mangia M, Moioli F (2001) Lactobacillus casei subsp. rhamnosus sepsis in a patient with ulcerative colitis. J Clin Gastroenterol 33:251-252.
13. Kunz AN, Noel JM, Fairchok MP (2004) Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr 38:457-458.
14. Liong M-T (2008) Safety of probiotics: Translocation and infection. Nutr Rev 66: 192-202.
15. Shim K-Y, et al. (2017) Microfluidic gut-on-a-chip with three-dimensional villi structure. Biomed Microdevices 19:37.
16. Wang Y, et al. (2018) Bioengineered systems and designer matrices that recapitulate the intestinal stem cell niche. Cell Mol Gastroenterol Hepatol 5:440-453.e1.
17. Shah P, et al. (2016) A microfluidics-based in vitro model of the gastrointestinal human-microbe interface. Nat Commun 7:11535.
18. Jalili-Firoozinezhad S, et al. (2018) Modeling radiation injury-induced cell death and countermeasure drug responses in a human gut-on-a-chip. Cell Death Dis 9:223.
19. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB (2014) Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal 20:1126-1167.
20. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G (1999) Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies. Immunity 10:387-398.
21. Sundberg JP, Elson CO, Bedigian H, Birkenmeier EH (1994) Spontaneous, heritable colitis in a new substrain of C3H/HeJ mice. Gastroenterology 107:1726-1735.
22. Rivera-Nieves J, et al. (2003) Emergence of perianal fistulizing disease in the SAMP1/ YitFc mouse, a spontaneous model of chronic ileitis. Gastroenterology 124:972-982.
23. Perse M, Cerar A (2012) Dextran sodium sulphate colitis mouse model: Traps and tricks. J Biomed Biotechnol 2012:718617.
24. Mähler M, et al. (1998) Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. Am J Physiol 274:G544-G551.
25. Yan Y, et al. (2009) Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLoS One 4:e6073.
26. Melgar S, Karlsson A, Michaëlsson E (2005) Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: Correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 288: G1328-G1338.
27. Iizuka M, Konno S (2011) Wound healing of intestinal epithelial cells. World J Gastroenterol 17:2161-2171.
28. Aruoma OI (1998) Free radicals, oxidative stress, and antioxidants in human health and disease. J Am Oil Chem Soc 75:199-212.
29. Nishiyama Y, Kataoka T, Yamato K, Taguchi T, Yamaoka K (2012) Suppression of dextran sulfate sodium-induced colitis in mice by radon inhalation. Mediators Inflamm 2012:239617.
30. Jones RM, Mercante JW, Neish AS (2012) Reactive oxygen production induced by the gut microbiota: Pharmacotherapeutic implications. Curr Med Chem 19:1519-1529.
31. Ma Q (2013) Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol 53:401-426.
32. Biswas SK (2016) Does the interdependence between oxidative stress and inflammation explain the antioxidant paradox? Oxid Med Cell Longev 2016:5698931.
33. Buelna-Chontal M, Zazueta C (2013) Redox activation of Nrf2 & NF-κB: A double end sword? Cell Signal 25:2548-2557.
34. Raetz CR, Whitfield C (2002) Lipopolysaccharide endotoxins. Annu Rev Biochem 71: 635-700.
35. Yu LC, Flynn AN, Turner JR, Buret AG (2005) SGLT-1-mediated glucose uptake protects intestinal epithelial cells against LPS-induced apoptosis and barrier defects: A novel cellular rescue mechanism? FASEB J 19:1822-1835.
36. Im E, Riegler FM, Pothoulakis C, Rhee SH (2012) Elevated lipopolysaccharide in the colon evokes intestinal inflammation, aggravated in immune modulator-impaired mice. Am J Physiol Gastrointest Liver Physiol 303:G490-G497.
37. Dai C, Zhao D-H, Jiang M (2012) VSL#3 probiotics regulate the intestinal epithelial barrier in vivo and in vitro via the p38 and ERK signaling pathways. Int J Mol Med 29: 202-208.
38. Madsen K, et al. (2001) Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121:580-591.
39. Isaacs K, Herfarth H (2008) Role of probiotic therapy in IBD. Inflamm Bowel Dis 14: 1597-1605.
40. Claes IJ, De Keersmaecker SC, Vanderleyden J, Lebeer S (2011) Lessons from probiotic-host interaction studies in murine models of experimental colitis. Mol Nutr Food Res 55:1441-1453.
41. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C (2002) Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: A rand-omised controlled trial with Lactobacillus GG. Gut 51:405-409.
42. Boyle RJ, Robins-Browne RM, Tang ML (2006) Probiotic use in clinical practice: What are the risks? Am J Clin Nutr 83:1256-1264, quiz 1446-1447.
43. Ordás I, Mould DR, Feagan BG, Sandborn WJ (2012) Anti-TNF monoclonal antibodies in inflammatory bowel disease: Pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 91:635-646.
44. Gisbert JP, Gomollón F, Maté J, Pajares JM (2002) Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: A systematic review. Dig Dis Sci 47: 471-488.